In summary, it is suggested that interfering in the SUMOylation of these proteins could be a potential strategy for the treatment of diseases induced by aberrant TGF-β signaling, which not only includes liver fibrosis but also HCC. This evidence concerns the gene TGFB1 and Hepatic fibrosis.